vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2021-4-95-109vtio-1364Research ArticleРегенеративная медицина и клеточные технологииRegenerative Medicine and Cell TechnologiesСовременные технологии инкапсуляции островков Лангерганса поджелудочной железы для коррекции сахарного диабета 1-го типаModern pancreatic islet encapsulation technologies for the treatment of type 1 diabetesЕрмаковаП. С.ErmakovaP. S.

Ермакова Полина Сергеевна

603104, Нижний Новгород, ул. Медицинская, 1

Тел. (987) 750-09-74

Polina Ermakova

1, Meditsinskaya str., Nizhny Novgorod, 603104, Russian Federation

Phone: (987) 750-09-74

bardina-polina@mail.ruЧеркасоваЕ. И.CherkasovaE. I.

Нижний Новгород

Nizhny Novgorod

ЛеньшинаН. А.LenshinaN. A.

Нижний Новгород

Nizhny Novgorod

КоневА. Н.KonevA. N.

Нижний Новгород

Nizhny Novgorod

БатенькинМ. А.BatenkinM. A.

Нижний Новгород

Nizhny Novgorod

ЧесноковС. А.ChesnokovS. A.

Нижний Новгород

Nizhny Novgorod

КучинД. М.KuchinD. M.

Нижний Новгород

Nizhny Novgorod

ЗагайноваЕ. В.ZagainovaE. V.

Нижний Новгород

Nizhny Novgorod

ЗагайновВ. Е.ZagainovV. E.

Нижний Новгород

Nizhny Novgorod

КашинаА. В.KashinaA. V.

Нижний Новгород

Nizhny Novgorod

ФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииРоссияPrivolzhsky Research Medical UniversityRussian FederationФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России; ФГАО УВО «Национальный исследовательский Нижегородский государственный университет имени Н.И. Лобачевского»РоссияPrivolzhsky Research Medical University; Lobachevsky State University of Nizhny NovgorodRussian FederationФГБУН «Институт металлоорганической химии имени Г.А. Разуваева Российской академии наук»РоссияRazuvaev Institute of Organometallic ChemistryRussian FederationФБУЗ «Приволжский окружной медицинский центр» ФМБА РоссииРоссияPrivolzhsky District Medical CenterRussian FederationФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России; ФГАО УВО «Национальный исследовательский Нижегородский государственный университет имени Н.И. Лобачевского»РоссияPrivolzhsky Research Medical University; Lobachevsky State University of Nizhny NovgorodRussian FederationФГБУ ВО «Приволжский исследовательский медицинский университет» Минздрава России; ФБУЗ «Приволжский окружной медицинский центр» ФМБА РоссииРоссияPrivolzhsky Research Medical University; Privolzhsky District Medical CenterRussian Federation20212210202123495109Copyright © Ермакова П.С., Черкасова Е.И., Леньшина Н.А., Конев А.Н., Батенькин М.А., Чесноков С.А., Кучин Д.М., Загайнова Е.В., Загайнов В.Е., Кашина А.В., 20222022Ермакова П.С., Черкасова Е.И., Леньшина Н.А., Конев А.Н., Батенькин М.А., Чесноков С.А., Кучин Д.М., Загайнова Е.В., Загайнов В.Е., Кашина А.В.Ermakova P.S., Cherkasova E.I., Lenshina N.A., Konev A.N., Batenkin M.A., Chesnokov S.A., Kuchin D.M., Zagainova E.V., Zagainov V.E., Kashina A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1364

В обзор включены результаты аналитических исследований по проблеме применения трансплантационных технологий инкапсулированных островков Лангерганса поджелудочной железы для компенсации сахарного диабета первого типа. Представлен обзор современных технологий получения капсул, подходов к стратегиям инкапсуляции, трансплантационных технологий инсулинозамещения: ауто-, алло-, ксенотрансплантаций; перспектив клеточной терапии при инсулинзависимых состояниях; современных подходов к инкапсуляции β-клеток, возможностей оптимизации используемых биоматериалов при инкапсуляции для повышения выживаемости трансплантируемых клеток и снижения негативных последствий для реципиента. Выявлены основные проблемы, которые необходимо решить для эффективной трансплантации инкапсулированных островков Лангерганса, и обозначены основные стратегии для перевода технологии инкапсуляции островков в медицинскую реальность.

The review includes the results of analytical research on the problem of application of pancreatic islet encapsulation technologies for compensation of type 1 diabetes. We present a review of modern encapsulation technologies, approaches to encapsulation strategies, insulin replacement technologies: auto-, allo- and xenotransplantation; prospects for cell therapy for insulin-dependent conditions; modern approaches to β-cell encapsulation, possibilities of optimization of encapsulation biomaterials to increase survival of transplanted cells and reduce adverse consequences for the recipient. The main problems that need to be solved for effective transplantation of encapsulated islets of Langerhans are identified and the main strategies for translating the islet encapsulation technology into medical reality are outlined.

поджелудочная железаостровки Лангергансаинкапсуляциятрансплантацияиммуносупрессиясахарный диабет первого типаpancreasislets of Langerhansencapsulationtransplantationimmunosuppressiontype 1 diabetesРабота выполнена при поддержке Министерства здравоохранения РФ (государственное задание № АААА-А20-120022590096-6 по теме «Создание технологии инкапсуляции островков поджелудочной железы для компенсации абсолютных инсулин-дефицитных состояний»)ReferencesRojas J, Bermudez V, Palmar J, Martínez MS, Olivar LC, Nava M, Tomey D et al. Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy. J Diabetes Res. 2018; 2018: 1–19. doi: 10.1155/2018/9601801.Rojas J, Bermudez V, Palmar J, Martínez MS, Olivar LC, Nava M, Tomey D et al. Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy. J Diabetes Res. 2018; 2018: 1–19. doi: 10.1155/2018/9601801.Aghazadeh Y, Nostro MC. Cell Therapy for Type 1 Diabetes: Current and Future Strategies. Curr Diab Rep. 2017; 17 (6): 37. doi: 10.1007/s11892-017-0863-6.Aghazadeh Y, Nostro MC. Cell Therapy for Type 1 Diabetes: Current and Future Strategies. Curr Diab Rep. 2017; 17 (6): 37. doi: 10.1007/s11892-017-0863-6.Primavera R, Razavi M, Kevadiya BD, Wang J, Vykunta A, Mascolo DD, Decuzzi P et al. Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates. Biofabrication. 2021; 13 (3). doi: 1 10.1088/1758-5090/abdcac.Primavera R, Razavi M, Kevadiya BD, Wang J, Vykunta A, Mascolo DD, Decuzzi P et al. Enhancing islet transplantation using a biocompatible collagen-PDMS bioscaffold enriched with dexamethasone-microplates. Biofabrication. 2021; 13 (3). doi: 1 10.1088/1758-5090/abdcac.Peloso A, Citro A, Zoro T, Cobianchi L, Kahler-Quesada A, Bianchi CM et al. Regenerative Medicine and Diabetes: Targeting the Extracellular Matrix Beyond the Stem Cell Approach and Encapsulation Technology. Front Endocrinol. 2018; 9: 445. doi: 10.3389/fendo.2018.00445.Peloso A, Citro A, Zoro T, Cobianchi L, Kahler-Quesada A, Bianchi CM et al. Regenerative Medicine and Diabetes: Targeting the Extracellular Matrix Beyond the Stem Cell Approach and Encapsulation Technology. Front Endocrinol. 2018; 9: 445. doi: 10.3389/fendo.2018.00445.Yoshihara E, O’Connor C, Gasser E. Immune-evasive human islet-like organoids ameliorate diabetes. Nature. 2020; 586 (7830): 606–611. doi: 10.1038/s41586-020-2631-z.Yoshihara E, O’Connor C, Gasser E. Immune-evasive human islet-like organoids ameliorate diabetes. Nature. 2020; 586 (7830): 606–611. doi: 10.1038/s41586-020-2631-z.Strand BL, Coron AE, Skjak-Braek G. Current and future perspectives on alginate encapsulated pancreatic islet. Stem Cells Transl Med. 2017; 6 (4): 1053–1058. doi: 10.1002/sctm.16-0116.Strand BL, Coron AE, Skjak-Braek G. Current and future perspectives on alginate encapsulated pancreatic islet. Stem Cells Transl Med. 2017; 6 (4): 1053–1058. doi: 10.1002/sctm.16-0116.Vasile C, Pamfil D, Stoleru E, Baican M. New Developments in Medical Applications of Hybrid Hydrogels Containing Natural Polymers. Molecules. 2020 Mar 27; 25 (7): 1539. doi: 10.3390/molecules25071539.Vasile C, Pamfil D, Stoleru E, Baican M. New Developments in Medical Applications of Hybrid Hydrogels Containing Natural Polymers. Molecules. 2020 Mar 27; 25 (7): 1539. doi: 10.3390/molecules25071539.Hu S, de Vos P. Polymeric approaches to reduce tissue responses against devices applied for islet-cell encapsulation. Front Bioeng Biotechnol. 2019; 7: 134. doi: 10.3389/fbioe.2019.00134.Hu S, de Vos P. Polymeric approaches to reduce tissue responses against devices applied for islet-cell encapsulation. Front Bioeng Biotechnol. 2019; 7: 134. doi: 10.3389/fbioe.2019.00134.Gazda LS, Vinerean HV. Laramore MA, Hall RD, Carraway W, Smith BH. Pravastatin Improves Glucose Regulation and Biocompatibility of Agarose Encapsulated Porcine Islets following Transplantation into Pancreatectomized Dogs. J Diabetes Res. 2014; 2014: 405362. doi: 10.1155/2014/405362.Gazda LS, Vinerean HV. Laramore MA, Hall RD, Carraway W, Smith BH. Pravastatin Improves Glucose Regulation and Biocompatibility of Agarose Encapsulated Porcine Islets following Transplantation into Pancreatectomized Dogs. J Diabetes Res. 2014; 2014: 405362. doi: 10.1155/2014/405362.Iwata H, Takagi T, Amemiya H. Agarose microcapsule applied in islet xenografts (hamster to mouse). Transplant Proc. 1992; 24 (3): 952.Iwata H, Takagi T, Amemiya H. Agarose microcapsule applied in islet xenografts (hamster to mouse). Transplant Proc. 1992; 24 (3): 952.Sabatini V, Pellicano L, Farina H, Pargoletti E, Annunziata L, Ortenzi MA et al. Design of New Polyacrylate Microcapsules to Modify the Water-Soluble Active Substances Release. Polymers. 2021; 13 (809). doi: 10.3390/polym13050809.Sabatini V, Pellicano L, Farina H, Pargoletti E, Annunziata L, Ortenzi MA et al. Design of New Polyacrylate Microcapsules to Modify the Water-Soluble Active Substances Release. Polymers. 2021; 13 (809). doi: 10.3390/polym13050809.Dupuy B, Gin H, Baquey C, Ducassou D. In situ polymerization of a microencapsulating medium round living cells. J Biomed Mater Res. 1988; 22 (11): 1061–1070. doi: 10.1002/jbm.820221109.Dupuy B, Gin H, Baquey C, Ducassou D. In situ polymerization of a microencapsulating medium round living cells. J Biomed Mater Res. 1988; 22 (11): 1061–1070. doi: 10.1002/jbm.820221109.Tun T, Inoue K, Hayashi H, Aung T, Gua Y-J, Doia R et al. A newly developed three-layer agarose microcapsule for a promising biohybrid artificial pancreas: rat to mouse xenotransplantation. Cell Transplant. 1996; 5 (5 Suppl 1): 59–63. doi: 10.1016/0963-6897(96)00042-5.Tun T, Inoue K, Hayashi H, Aung T, Gua Y-J, Doia R et al. A newly developed three-layer agarose microcapsule for a promising biohybrid artificial pancreas: rat to mouse xenotransplantation. Cell Transplant. 1996; 5 (5 Suppl 1): 59–63. doi: 10.1016/0963-6897(96)00042-5.Jain K, Yang H, Asina SK, Patel SG, Desai J, Diehl C et al. Long-term preservation of islets of Langerhans in hydrophilic macrobeads. Transplantation. 1996; 61 (4):532–536. doi: 10.1097/00007890-199602270-00003.Jain K, Yang H, Asina SK, Patel SG, Desai J, Diehl C et al. Long-term preservation of islets of Langerhans in hydrophilic macrobeads. Transplantation. 1996; 61 (4):532–536. doi: 10.1097/00007890-199602270-00003.Barkai U, Rotem A, de Vos P. Survival of encapsulated islets: More than a membrane story. World J Transplant. 2016; 6 (1): 69–90. doi: 10.5500/wjt.v6.i1.69.Barkai U, Rotem A, de Vos P. Survival of encapsulated islets: More than a membrane story. World J Transplant. 2016; 6 (1): 69–90. doi: 10.5500/wjt.v6.i1.69.Basta G, Montanucci P, Calafiore R. Microencapsulation of cells and molecular therapy of type 1 diabetes mellitus: The actual state and future perspectives between promise and progress. J Diabetes Investig. 2020; 12 (3). doi: 10.1111/jdi.13372.Basta G, Montanucci P, Calafiore R. Microencapsulation of cells and molecular therapy of type 1 diabetes mellitus: The actual state and future perspectives between promise and progress. J Diabetes Investig. 2020; 12 (3). doi: 10.1111/jdi.13372.Vaithilingam V, Bal S, Tuch BE. Encapsulated Islet Transplantation: Where Do We Stand? Rev Diabet Stud. 2017; 14 (1): 51–78. doi: 10.1900/RDS.2017.14.51.Vaithilingam V, Bal S, Tuch BE. Encapsulated Islet Transplantation: Where Do We Stand? Rev Diabet Stud. 2017; 14 (1): 51–78. doi: 10.1900/RDS.2017.14.51.Simó G, Fernández-Fernández E, Vila-Crespo J, Ruipérez V, Rodríguez-Nogales JM. Research progress in coating techniques of alginate gel polymer for cell encapsulation. Carbohydr Polym. 2017; 170: 1–14. doi: 10.1016/j.carbpol.2017.04.013.Simó G, Fernández-Fernández E, Vila-Crespo J, Ruipérez V, Rodríguez-Nogales JM. Research progress in coating techniques of alginate gel polymer for cell encapsulation. Carbohydr Polym. 2017; 170: 1–14. doi: 10.1016/j.carbpol.2017.04.013.Ernst AU, Bowers DT, Wang L-H, Shariati K, Plesser MD, Brown NK, Mehrabyan T et al. Nanotechnology in cell replacement therapies for type 1 diabetes. Adv Drug Deliv Rev. 2019; 139: 116–138. doi: 10.1016/j.addr.2019.01.013.Ernst AU, Bowers DT, Wang L-H, Shariati K, Plesser MD, Brown NK, Mehrabyan T et al. Nanotechnology in cell replacement therapies for type 1 diabetes. Adv Drug Deliv Rev. 2019; 139: 116–138. doi: 10.1016/j.addr.2019.01.013.Bochenek MA, Veiseh O, Vegas AJ. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat Biomed Eng. 2018; 2 (11): 810–821. doi: 10.1038/s41551-018-0275-1.Bochenek MA, Veiseh O, Vegas AJ. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat Biomed Eng. 2018; 2 (11): 810–821. doi: 10.1038/s41551-018-0275-1.Vaithilingam V, Kollarikova G, Qi M, Lacik I. Effect of prolonged gelling time on the intrinsic properties of barium alginate microcapsules and its biocompatibility. J Microencapsl. 2011; 28 (6): 499–507.Vaithilingam V, Kollarikova G, Qi M, Lacik I. Effect of prolonged gelling time on the intrinsic properties of barium alginate microcapsules and its biocompatibility. J Microencapsl. 2011; 28 (6): 499–507.Qi M, Lacik I, Kolláriková G, Strand BL, Formo K, Wang Y, Marchese E et al. A recommended laparoscopic procedure for implantation of microcapsules in the peritoneal cavity of non-human primates. J Surg Res. 2011; 168 (1): 117–123. doi: 10.1016/j.jss.2011.01.040.Qi M, Lacik I, Kolláriková G, Strand BL, Formo K, Wang Y, Marchese E et al. A recommended laparoscopic procedure for implantation of microcapsules in the peritoneal cavity of non-human primates. J Surg Res. 2011; 168 (1): 117–123. doi: 10.1016/j.jss.2011.01.040.Ellis CE, Korbutt GS. Chitosan-based biomaterials for treatment of diabetes. Chitosan Based Biomaterials. 2017; 91–113. doi: 10.1016/B978-0-08-100228-5.00004-3.Ellis CE, Korbutt GS. Chitosan-based biomaterials for treatment of diabetes. Chitosan Based Biomaterials. 2017; 91–113. doi: 10.1016/B978-0-08-100228-5.00004-3.Kim MJ, Park H-S, Kim J-W, Lee E-Y, Rhee M, You Y-H et al. Suppression of Fibrotic Reactions of Chitosan-Alginate Microcapsules Containing Porcine Islets by Dexamethasone Surface Coating. Endocrinol Metab (Seoul). 2021; 36 (1): 146–156. doi: 10.3803/EnM.2021.879.Kim MJ, Park H-S, Kim J-W, Lee E-Y, Rhee M, You Y-H et al. Suppression of Fibrotic Reactions of Chitosan-Alginate Microcapsules Containing Porcine Islets by Dexamethasone Surface Coating. Endocrinol Metab (Seoul). 2021; 36 (1): 146–156. doi: 10.3803/EnM.2021.879.Lin K, Zhang D, Macedo MH, Cui W, Sarmento B, Shen G. Advanced Collagen-Based Biomaterials for Regenerative Biomedicine. Advanced Functional Materials. 2019; 29 (3). doi: 10.1002/adfm.201804943.Lin K, Zhang D, Macedo MH, Cui W, Sarmento B, Shen G. Advanced Collagen-Based Biomaterials for Regenerative Biomedicine. Advanced Functional Materials. 2019; 29 (3). doi: 10.1002/adfm.201804943.Silvipriya KS, Kumar KK, Bhat AR, Kumar D, John A, lakshmanan P. Collagen: Animal Sources and Biomedical Application. JAPS. 2015; 5 (03): 123–127. doi: 10.7324/JAPS.2015.50322.Silvipriya KS, Kumar KK, Bhat AR, Kumar D, John A, lakshmanan P. Collagen: Animal Sources and Biomedical Application. JAPS. 2015; 5 (03): 123–127. doi: 10.7324/JAPS.2015.50322.Lee CH, Singla A, Lee Y. Biomedical applications of collagen. Int J Pharm. 2001; 221 (1–2): 1–22. doi: 10.1016/s0378-5173(01)00691-3.Lee CH, Singla A, Lee Y. Biomedical applications of collagen. Int J Pharm. 2001; 221 (1–2): 1–22. doi: 10.1016/s0378-5173(01)00691-3.Yin C, Chia SM. Quek CH, YuH, Zhuo R-X, Leong KW, Maoad H-Q et al. Microcapsules with improved mechanical stability for hepatocyte culture. Biomaterials. 2003; 24 (10): 1771–1780. doi: 10.1016/S0142-9612(02)00580-X.Yin C, Chia SM. Quek CH, YuH, Zhuo R-X, Leong KW, Maoad H-Q et al. Microcapsules with improved mechanical stability for hepatocyte culture. Biomaterials. 2003; 24 (10): 1771–1780. doi: 10.1016/S0142-9612(02)00580-X.Marinucci L, Lilli C, Guerra M, Belcastro S, Becchetti E, Stabellini G et al. Biocompatibility of collagen membranes crosslinked with glutaraldehyde or diphenylphosphoryl azide: an in vitro study. J Biomed Mater Res A. 2003; 67 (2): 504–509. doi: 10.1002/jbm.a.10082.Marinucci L, Lilli C, Guerra M, Belcastro S, Becchetti E, Stabellini G et al. Biocompatibility of collagen membranes crosslinked with glutaraldehyde or diphenylphosphoryl azide: an in vitro study. J Biomed Mater Res A. 2003; 67 (2): 504–509. doi: 10.1002/jbm.a.10082.Song R, Murphy M, Li C, Ting K, Soo C, Zheng Z. Current development of biodegradable polymeric materials for biomedical applications. Drug Des Devel Ther. 2018; 12: 3117–3145. doi: 10.2147/DDDT.S165440.Song R, Murphy M, Li C, Ting K, Soo C, Zheng Z. Current development of biodegradable polymeric materials for biomedical applications. Drug Des Devel Ther. 2018; 12: 3117–3145. doi: 10.2147/DDDT.S165440.Gill I, Ballesteros A. Bioencapsulation within synthetic polymers (Part 1): sol–gel encapsulated biologicals. Trends Biotechnol. 2000; 18 (7): 282–296. doi: 10.1016/s0167-7799(00)01457-8.Gill I, Ballesteros A. Bioencapsulation within synthetic polymers (Part 1): sol–gel encapsulated biologicals. Trends Biotechnol. 2000; 18 (7): 282–296. doi: 10.1016/s0167-7799(00)01457-8.Klymiuk N, Ludwig B, Seissler J, Reichart B, Wolf E. Current Concepts of Using Pigs as a Source for Beta- Cell Replacement Therapy of Type 1 Diabetes. Curr Mol Biol Rep. 2016; 2: 73–82. doi: 10.1007/s40610-016-0039-1.Klymiuk N, Ludwig B, Seissler J, Reichart B, Wolf E. Current Concepts of Using Pigs as a Source for Beta- Cell Replacement Therapy of Type 1 Diabetes. Curr Mol Biol Rep. 2016; 2: 73–82. doi: 10.1007/s40610-016-0039-1.Schneider MC, Barnes CA, Bryant SJ. Characterization of the chondrocyte secretome in photoclickable poly(ethylene glycol) hydrogels. Biotechnol Bioeng. 2017; 114 (9): 2096–2108. doi: 10.1002/bit.26320.Schneider MC, Barnes CA, Bryant SJ. Characterization of the chondrocyte secretome in photoclickable poly(ethylene glycol) hydrogels. Biotechnol Bioeng. 2017; 114 (9): 2096–2108. doi: 10.1002/bit.26320.Carles-Carner M, Saleh LS, Bryant SJ. The effects of hydroxyapatite nanoparticles embedded in a MMPsensitive photoclickable PEG hydrogel on encapsulated MC3T3-E1 pre-osteoblasts. Biomed Mater. 2018; 13(4). doi: 10.1088/1748-605X/aabb31.Carles-Carner M, Saleh LS, Bryant SJ. The effects of hydroxyapatite nanoparticles embedded in a MMPsensitive photoclickable PEG hydrogel on encapsulated MC3T3-E1 pre-osteoblasts. Biomed Mater. 2018; 13(4). doi: 10.1088/1748-605X/aabb31.Nachlas ALY, Li S, Jha R. Human iPSC-derived mesenchymal stem cells encapsulated in PEGDA hydrogels mature into valve interstitial-like cells. Acta Biomater. 2018 Apr 15; 71: 235–246. doi: 10.1016/j.actbio.2018.02.025.Nachlas ALY, Li S, Jha R. Human iPSC-derived mesenchymal stem cells encapsulated in PEGDA hydrogels mature into valve interstitial-like cells. Acta Biomater. 2018 Apr 15; 71: 235–246. doi: 10.1016/j.actbio.2018.02.025.Qin X-H, Ovsianikov A, Stampfl J, Liska R. Additive manufacturing of photosensitive hydrogels for tissue engineering applications. BioNanoMaterials. 2014; 15(3–4): 49–70. doi: 10.1515/bnm-2014-0008.Qin X-H, Ovsianikov A, Stampfl J, Liska R. Additive manufacturing of photosensitive hydrogels for tissue engineering applications. BioNanoMaterials. 2014; 15(3–4): 49–70. doi: 10.1515/bnm-2014-0008.Cellesi F, Tirelli NA. New process for cell microencapsulation and other biomaterial applications: thermal gelation and chemical cross-linking in «tandem». J Mater Sci Mater Med. 2005; 16 (6): 559–565. doi: 10.1007/s10856-005-0532-1.Cellesi F, Tirelli NA. New process for cell microencapsulation and other biomaterial applications: thermal gelation and chemical cross-linking in «tandem». J Mater Sci Mater Med. 2005; 16 (6): 559–565. doi: 10.1007/s10856-005-0532-1.Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and macrophages against PEG-grafted pancreatic islets. Biomaterials. 2004; 25 (17): 3663–3669. doi: 10.1016/j.biomaterials.2003.10.062.Jang JY, Lee DY, Park SJ, Byun Y. Immune reactions of lymphocytes and macrophages against PEG-grafted pancreatic islets. Biomaterials. 2004; 25 (17): 3663–3669. doi: 10.1016/j.biomaterials.2003.10.062.Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem. 2006; 17 (4): 1036–1042. doi: 10.1021/bc060023o.Cheung CY, Anseth KS. Synthesis of immunoisolation barriers that provide localized immunosuppression for encapsulated pancreatic islets. Bioconjug Chem. 2006; 17 (4): 1036–1042. doi: 10.1021/bc060023o.Lin CC, Metters AT, Anseth KS. Functional PEG–peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials. 2009; 30 (28): 4907–4914. doi: 10.1016/j.biomaterials.2009.05.083.Lin CC, Metters AT, Anseth KS. Functional PEG–peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFalpha. Biomaterials. 2009; 30 (28): 4907–4914. doi: 10.1016/j.biomaterials.2009.05.083.Dimitrioglou N, Kanelli M, Papageorgiou E, Karatzas T, Hatziavramidis D. Paving the way for successful islet encapsulation. Drug Discov Today. 2019; 24(3): 737–748. doi: 10.1016/j.drudis.2019.01.020.Dimitrioglou N, Kanelli M, Papageorgiou E, Karatzas T, Hatziavramidis D. Paving the way for successful islet encapsulation. Drug Discov Today. 2019; 24(3): 737–748. doi: 10.1016/j.drudis.2019.01.020.Hwang PTJ, Shah DK, Garcia JA, Bae CY, Lim D-J, Huiszoon RC at al. Progress and challenges of the bioartificial pancreas. Nano Converg. 2016; 3 (1): 28. doi: 10.1186/s40580-016-0088-4.Hwang PTJ, Shah DK, Garcia JA, Bae CY, Lim D-J, Huiszoon RC at al. Progress and challenges of the bioartificial pancreas. Nano Converg. 2016; 3 (1): 28. doi: 10.1186/s40580-016-0088-4.Song S, Roy S. Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices. Biotechnol Bioeng. 2016; 113 (7): 1381–13402. doi: 10.1002/bit.25895.Song S, Roy S. Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices. Biotechnol Bioeng. 2016; 113 (7): 1381–13402. doi: 10.1002/bit.25895.Gamble A, Pepper AR, Bruni A, Shapiro AMJ. The journey of islet cell transplantation and future development. Islets. 2018; 10 (2): 80–94. doi: 10.1080/19382014.2018.Gamble A, Pepper AR, Bruni A, Shapiro AMJ. The journey of islet cell transplantation and future development. Islets. 2018; 10 (2): 80–94. doi: 10.1080/19382014.2018.Lamb M, Storrs R, Li S, Liang O et al. Function and viability of human islets encapsulated in alginate sheets: in vitro and in vivo culture. Transplant Proc. 2011; 43 (9):3265–3266. doi: 10.1016/j.transproceed.2011.10.028.Lamb M, Storrs R, Li S, Liang O et al. Function and viability of human islets encapsulated in alginate sheets: in vitro and in vivo culture. Transplant Proc. 2011; 43 (9):3265–3266. doi: 10.1016/j.transproceed.2011.10.028.Boettler T, Schneider D, Cheng Y, Kadoya K, Brandon EP, Martinson L et al. Pancreatic tissue transplanted in theracyte encapsulation devices is protected and prevents hyperglycemia in a mouse model of immunemediated diabetes. Cell Transplant. 2016; 25 (3): 609–614. doi: 10.3727/096368915X688939.Boettler T, Schneider D, Cheng Y, Kadoya K, Brandon EP, Martinson L et al. Pancreatic tissue transplanted in theracyte encapsulation devices is protected and prevents hyperglycemia in a mouse model of immunemediated diabetes. Cell Transplant. 2016; 25 (3): 609–614. doi: 10.3727/096368915X688939.Lysy PA, Corritore E, Sokal EM. New Insights into Diabetes Cell Therapy. Curr Diab Rep. 2016; 16: 38. doi: 10.1007/s11892-016-0729-3.Lysy PA, Corritore E, Sokal EM. New Insights into Diabetes Cell Therapy. Curr Diab Rep. 2016; 16: 38. doi: 10.1007/s11892-016-0729-3.Bartlett ST, Markmann JF, Johnson P, Korsgren O, Hering BJ, Scharp D et al. Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement. Transplantation. 2016; 100 (Suppl 2): S1–44. doi: 10.1097/TP.0000000000001055.Bartlett ST, Markmann JF, Johnson P, Korsgren O, Hering BJ, Scharp D et al. Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement. Transplantation. 2016; 100 (Suppl 2): S1–44. doi: 10.1097/TP.0000000000001055.Cañibano-Hernández A, Burgo LSD, Espona-Noguera A, Ciriza J, Pedraz JL. Current advanced therapy cell-based medicinal products for type-1-diabetes treatment. Int J Pharm. 2018; 543 (1–2): 107–120. doi: 10.1016/j.ijpharm.2018.03.041.Cañibano-Hernández A, Burgo LSD, Espona-Noguera A, Ciriza J, Pedraz JL. Current advanced therapy cell-based medicinal products for type-1-diabetes treatment. Int J Pharm. 2018; 543 (1–2): 107–120. doi: 10.1016/j.ijpharm.2018.03.041.Ludwig B, Rotem A, Schmid J et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci USA. 2012; 109 (13): 5022–5027. doi: 10.1073/pnas.1201868109.Ludwig B, Rotem A, Schmid J et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci USA. 2012; 109 (13): 5022–5027. doi: 10.1073/pnas.1201868109.Neufeld T, Ludwig B, Barkai U et al. The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One. 2013; 8 (8). doi: 10.1371/journal.pone.0070150.Neufeld T, Ludwig B, Barkai U et al. The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One. 2013; 8 (8). doi: 10.1371/journal.pone.0070150.Gholipourmalekabadi M, Zhao S, Harrison SB, Mozafari M, Seifalian MA. Oxygen-generating biomaterials: A new, viable paradigm for tissue engineering? Trends Biotechnol. 2016; 34 (12): 1010–1021. doi: 10.1016/j.tibtech.2016.05.012.Gholipourmalekabadi M, Zhao S, Harrison SB, Mozafari M, Seifalian MA. Oxygen-generating biomaterials: A new, viable paradigm for tissue engineering? Trends Biotechnol. 2016; 34 (12): 1010–1021. doi: 10.1016/j.tibtech.2016.05.012.Rausa RA, Nawawi FWMW, Nasaruddin RR. Alginate and alginate composites for biomedical applications. AJPCR. 2021; 16 (3): 280–306. doi: 10.1016/j.ajps.2020.10.001.Rausa RA, Nawawi FWMW, Nasaruddin RR. Alginate and alginate composites for biomedical applications. AJPCR. 2021; 16 (3): 280–306. doi: 10.1016/j.ajps.2020.10.001.Pandolfi V, Pereira U, Dufresne M, Legallais C. Alginate- Based Cell Microencapsulation for Tissue Engineering and Regenerative Medicine. Curr Pharm Des. 2017; 23 (26): 3833–3844. doi: 10.2174/1381612823666170609084016.Pandolfi V, Pereira U, Dufresne M, Legallais C. Alginate- Based Cell Microencapsulation for Tissue Engineering and Regenerative Medicine. Curr Pharm Des. 2017; 23 (26): 3833–3844. doi: 10.2174/1381612823666170609084016.Fernando IPS, Lee WW, Han EJ, Ahn G. Alginate-based nanomaterials: Fabrication techniques, properties, and applications. Chemical Engineering Journal. 2020; 391. doi: 10.1016/j.cej.2019.123823.Fernando IPS, Lee WW, Han EJ, Ahn G. Alginate-based nanomaterials: Fabrication techniques, properties, and applications. Chemical Engineering Journal. 2020; 391. doi: 10.1016/j.cej.2019.123823.Mallett AG, Korbutt GS. Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng Part A. 2009; 15 (6):1301–1309. doi: 10.1089/ten.tea.2008.0118.Mallett AG, Korbutt GS. Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng Part A. 2009; 15 (6):1301–1309. doi: 10.1089/ten.tea.2008.0118.Ashimova A, Yegorov S, Negmetzhanov B, Hortelano G. Cell Encapsulation Within Alginate Microcapsules: Immunological Challenges and Outlook. Front Bioeng Biotechnol. 2019; 7: 380. doi: 10.3389/fbioe.2019.00380.Ashimova A, Yegorov S, Negmetzhanov B, Hortelano G. Cell Encapsulation Within Alginate Microcapsules: Immunological Challenges and Outlook. Front Bioeng Biotechnol. 2019; 7: 380. doi: 10.3389/fbioe.2019.00380.Paredes-Juarez GA, de Haan BJ, Faas MM, de Vos PA. Technology platform to test the efficacy of purification of alginate. Materials (Basel). 2014; 7 (3): 2087–2103. doi: 10.3390/ma7032087.Paredes-Juarez GA, de Haan BJ, Faas MM, de Vos PA. Technology platform to test the efficacy of purification of alginate. Materials (Basel). 2014; 7 (3): 2087–2103. doi: 10.3390/ma7032087.De Groot M, Schuurs TA, van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res. 2004; 121 (1): 141–150. doi: 10.1016/j.jss.2004.02.018.De Groot M, Schuurs TA, van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res. 2004; 121 (1): 141–150. doi: 10.1016/j.jss.2004.02.018.Mitchell A, Johnson B. Reactive polymers and microcapsules. McMaster: 2020.Mitchell A, Johnson B. Reactive polymers and microcapsules. McMaster: 2020.De Vos P, de Haan B, van Schilfgaarde R. Effect of the alginate composition on the biocompatibility of alginatepolylysine microcapsules. Biomaterials. 1997; 18 (3):273–278. doi: 10.1016/s0142-9612(96)00135-4.De Vos P, de Haan B, van Schilfgaarde R. Effect of the alginate composition on the biocompatibility of alginatepolylysine microcapsules. Biomaterials. 1997; 18 (3):273–278. doi: 10.1016/s0142-9612(96)00135-4.Schneider S, Feilen PJ, Kraus O, Haase T, Sagban TA, Lehr H-A et al. Biocompatibility of alginates for grafting: impact of alginate molecular weight. Artif Cells Blood Substit Immobil Biotechnol. 2003; 31 (4): 383–394. doi: 10.1081/bio-120025409.Schneider S, Feilen PJ, Kraus O, Haase T, Sagban TA, Lehr H-A et al. Biocompatibility of alginates for grafting: impact of alginate molecular weight. Artif Cells Blood Substit Immobil Biotechnol. 2003; 31 (4): 383–394. doi: 10.1081/bio-120025409.Robitaille R, Pariseau JF, Leblond FA, Lamoureux M, Lepage Y, Hallé JP. Studies on small (<350 microm) alginate-poly-L-lysine microcapsules. III. Biocompatibility Of smaller versus standard microcapsules. J Biomed Mater Res. 1999; 44 (1): 116–120. doi: 10.1002/(sici)1097-4636(199901)44:1<116::aidjbm13>3.0.co;2-9.Robitaille R, Pariseau JF, Leblond FA, Lamoureux M, Lepage Y, Hallé JP. Studies on small (<350 microm) alginate-poly-L-lysine microcapsules. III. Biocompatibility Of smaller versus standard microcapsules. J Biomed Mater Res. 1999; 44 (1): 116–120. doi: 10.1002/(sici)1097-4636(199901)44:1<116::aidjbm13>3.0.co;2-9.Lum ZP, Krestow M, Tai IT, Vacek I, Sun AM. Xenografts of rat islets into diabetic mice. An evaluation of new smaller capsules. Transplantation. 1992; 53 (6):1180–1183. doi: 10.1097/00007890-199206000-00002.Lum ZP, Krestow M, Tai IT, Vacek I, Sun AM. Xenografts of rat islets into diabetic mice. An evaluation of new smaller capsules. Transplantation. 1992; 53 (6):1180–1183. doi: 10.1097/00007890-199206000-00002.Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR et al. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat Mater. 2015; 14 (6): 643–651. doi: 10.1038/nmat4290.Veiseh O, Doloff JC, Ma M, Vegas AJ, Tam HH, Bader AR et al. Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates. Nat Mater. 2015; 14 (6): 643–651. doi: 10.1038/nmat4290.Haque MR, Kim J, Park H, Lee HS, Lee KW, Al-Hilal TA et al. Xenotransplantation of layer-by-layer encapsulated nonhuman primate islets with a specified immunosuppressive drug protocol. J Control Release. 2017; 258: 10–21. doi: 10.1016/j.jconrel.2017.04.021.Haque MR, Kim J, Park H, Lee HS, Lee KW, Al-Hilal TA et al. Xenotransplantation of layer-by-layer encapsulated nonhuman primate islets with a specified immunosuppressive drug protocol. J Control Release. 2017; 258: 10–21. doi: 10.1016/j.jconrel.2017.04.021.Park H, Haque MR, Park JB, Lee KW, Lee S, Kwon Y et al. Polymeric nano-shielded islets with heparin-polyethylene glycol in a non-human primate model. Biomaterials. 2018; 171: 164–177. doi: 10.1016/j.biomaterials.2018.04.028.Park H, Haque MR, Park JB, Lee KW, Lee S, Kwon Y et al. Polymeric nano-shielded islets with heparin-polyethylene glycol in a non-human primate model. Biomaterials. 2018; 171: 164–177. doi: 10.1016/j.biomaterials.2018.04.028.Lou S, Zhang X, Zhang J, Deng J, Kong D, Li C. Pancreatic islet surface bioengineering with a heparinincorporated starPEG nanofilm. Mater Sci Eng C Mater Biol Appl. 2017; 78: 24–31. doi: 10.1016/j.msec.2017.03.295.Lou S, Zhang X, Zhang J, Deng J, Kong D, Li C. Pancreatic islet surface bioengineering with a heparinincorporated starPEG nanofilm. Mater Sci Eng C Mater Biol Appl. 2017; 78: 24–31. doi: 10.1016/j.msec.2017.03.295.Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994; 343 (8903): 950–951. doi: 10.1016/s0140-6736(94)90067-1.Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994; 343 (8903): 950–951. doi: 10.1016/s0140-6736(94)90067-1.Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: First two cases. Diabetes Care. 2006; 29 (1): 137–138. doi: 10.2337/diacare.29.1.137.Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: First two cases. Diabetes Care. 2006; 29 (1): 137–138. doi: 10.2337/diacare.29.1.137.Touch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009; 32 (10): 1887–1889. doi: 10.2337/dc09-0744.Touch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009; 32 (10): 1887–1889. doi: 10.2337/dc09-0744.Graham ML, Schuurman H-J. Pancreatic islet xenotransplantation. Drug Discovery Today: Disease Models. 2017; 23: 43–50. doi: 10.1016/j.ddmod.2017.11.004.Graham ML, Schuurman H-J. Pancreatic islet xenotransplantation. Drug Discovery Today: Disease Models. 2017; 23: 43–50. doi: 10.1016/j.ddmod.2017.11.004.Nagaraju S, Bottino R Wijkstrom M, Trucco M, Cooper DKC. Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation. 2015; 22 (1): 7–19. doi: 10.1111/xen.12130.Nagaraju S, Bottino R Wijkstrom M, Trucco M, Cooper DKC. Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation. 2015; 22 (1): 7–19. doi: 10.1111/xen.12130.Пеллегрини С, Сорди В, Пьемонти Л. Замещение β-клеток поджелудочной железы при сахарном диабете. Сахарный диабет. 2013; (3): 11–20.Pellegrini C, Sordi B, Piemonti L. Pancreatic β-cell replacement in diabetes mellitus. Diabetes. 2013; (3): 11–20.Klymiuk N, van Buerck L, Bahr A, Offers M, Kessler B, Wuensch A et al. Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice. Diabetes. 2012; 61 (6): 1527–15232. doi: 10.2337/db11-1325.Klymiuk N, van Buerck L, Bahr A, Offers M, Kessler B, Wuensch A et al. Xenografted islet cell clusters from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice. Diabetes. 2012; 61 (6): 1527–15232. doi: 10.2337/db11-1325.Ludwig B, Ludwig S. Transplantable bioartificial pancreas devices: current status and future prospects. Langenbecks Arch Surg. 2015; 400 (5): 531–540. doi: 10.1007/s00423-015-1314-y.Ludwig B, Ludwig S. Transplantable bioartificial pancreas devices: current status and future prospects. Langenbecks Arch Surg. 2015; 400 (5): 531–540. doi: 10.1007/s00423-015-1314-y.Korbutt GS, Elliott JF, Rajotte RV. Co-transplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes. 1997; 46 (2): 317–322. doi: 10.2337/diab.46.2.317.Korbutt GS, Elliott JF, Rajotte RV. Co-transplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes. 1997; 46 (2): 317–322. doi: 10.2337/diab.46.2.317.Dufour JM, Rajotte RV, Kin T, Korbutt GS. Immunoprotection of rat islet xenografts by cotransplantation with sertoli cells and a single injection of antilymphocyte serum. Transplantation. 2003; 75 (9): 1594–1596. doi: 10.1097/01.TP.0000058748.00707.88.Dufour JM, Rajotte RV, Kin T, Korbutt GS. Immunoprotection of rat islet xenografts by cotransplantation with sertoli cells and a single injection of antilymphocyte serum. Transplantation. 2003; 75 (9): 1594–1596. doi: 10.1097/01.TP.0000058748.00707.88.Korbutt GS, Suarez-Pinzon WL, Power RF, Rajotte RV, Rabinovitch A. Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice. Diabetologia. 2000; 43 (4):474–480. doi: 10.1007/s001250051331.Korbutt GS, Suarez-Pinzon WL, Power RF, Rajotte RV, Rabinovitch A. Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obese diabetic mice. Diabetologia. 2000; 43 (4):474–480. doi: 10.1007/s001250051331.Luca G, Calafiore R, Basta G, Ricci M, Calvitti M, Neri L et al. Improved function of rat islets upon comicroencapsulation with Sertoli’s cells in alginate/poly-Lornithine. AAPS PharmSciTech. 2001; 2 (3). doi: 10.1208/pt020315.Luca G, Calafiore R, Basta G, Ricci M, Calvitti M, Neri L et al. Improved function of rat islets upon comicroencapsulation with Sertoli’s cells in alginate/poly-Lornithine. AAPS PharmSciTech. 2001; 2 (3). doi: 10.1208/pt020315.Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006; 312 (12): 2169–2179. doi: 10.1016/j.yexcr.2006.03.019.Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res. 2006; 312 (12): 2169–2179. doi: 10.1016/j.yexcr.2006.03.019.Longoni B, Szilagyi E, Quaranta P, Paoli GT, Tripodi S, Urbani S et al. Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technol Ther. 2010; 12 (6):435–446. doi: 10.1089/dia.2009.0154.Longoni B, Szilagyi E, Quaranta P, Paoli GT, Tripodi S, Urbani S et al. Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technol Ther. 2010; 12 (6):435–446. doi: 10.1089/dia.2009.0154.Kerby A, Jones ES, Jones PM, King AJ. Cotransplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. Cytotherapy. 2013; 15 (2): 192–200. doi: 10.1016/j.jcyt.2012.10.018.Kerby A, Jones ES, Jones PM, King AJ. Cotransplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. Cytotherapy. 2013; 15 (2): 192–200. doi: 10.1016/j.jcyt.2012.10.018.Jourdan G, Dusseault J, Benhamou PY. Co-encapsulation of bioengineered IGF-II-producing cells and pancreatic islets: effect on beta-cell survival. Gene Therapy. 2011; 18: 539–545. doi: 10.1038/gt.2010.166.Jourdan G, Dusseault J, Benhamou PY. Co-encapsulation of bioengineered IGF-II-producing cells and pancreatic islets: effect on beta-cell survival. Gene Therapy. 2011; 18: 539–545. doi: 10.1038/gt.2010.166.Babiker NE, Gassoum A, Abdelraheem NE, Arbab MA, ALDeaf SAH, El-Sheikh MAA et al. The progress of stem cells in the treatment of diabetes mellitus type 1. Progress in Stem Cell. 2017; 1: 175–188.Babiker NE, Gassoum A, Abdelraheem NE, Arbab MA, ALDeaf SAH, El-Sheikh MAA et al. The progress of stem cells in the treatment of diabetes mellitus type 1. Progress in Stem Cell. 2017; 1: 175–188.Ilic D, Devito L, Miere C, Codognotto S. Human embryonic and induced pluripotent stem cells in clinical trials. Br Med Bull. 2015; 116: 19–27. doi: 10.1093/bmb/ldv045.Ilic D, Devito L, Miere C, Codognotto S. Human embryonic and induced pluripotent stem cells in clinical trials. Br Med Bull. 2015; 116: 19–27. doi: 10.1093/bmb/ldv045.Zhou Q, Melton DA. Pancreas regeneration. Nature. 2018; 557 (7705): 351–358. doi: 10.1038/s41586-018-0088-0.Zhou Q, Melton DA. Pancreas regeneration. Nature. 2018; 557 (7705): 351–358. doi: 10.1038/s41586-018-0088-0.Dang LT-T, Bui AN-T, Pham VM, Phan NK, Pham PV. Production of islet-like insulin-producing cell clusters in vitro from adiposederived stem cells. Biomedical Research and Therapy. 2015; 2 (1): 184–192. doi: 10.7603/s40730-015-0003-3.Dang LT-T, Bui AN-T, Pham VM, Phan NK, Pham PV. Production of islet-like insulin-producing cell clusters in vitro from adiposederived stem cells. Biomedical Research and Therapy. 2015; 2 (1): 184–192. doi: 10.7603/s40730-015-0003-3.Борисов МА, Петракова ОС, Гвазава ИГ, Калис- тратова ЕН, Васильев АВ. Клеточные подходы к лечению инсулинзависимого диабета. Аcta Nature (русскоязычная версия). 2016; 8 (3): 34–48.Borisov MA, Petrakova OS, Gvazava IG, Kalistratova EN, Vasiliev AV. Cellular approaches to the treatment of insulin-dependent diabetes. Аcta Nature (Russian version). 2016; 8 (3): 34–48.Hashemian SJ, Kouhnavard M, Nasli-Esfahani E. Mesenchymal stem cells: rising concerns over their application in treatment of type one diabetes mellitus. J Diabetes Res. 2015; 2015: 675103. doi: 10.1155/2015/675103.Hashemian SJ, Kouhnavard M, Nasli-Esfahani E. Mesenchymal stem cells: rising concerns over their application in treatment of type one diabetes mellitus. J Diabetes Res. 2015; 2015: 675103. doi: 10.1155/2015/675103.Li W, Cavelti-Weder C, Zhang Y, Clement K, Donovan S, Gonzalez G et al. Long-term persistence and development of induced pancreatic β cells generated by lineage conversion of acinar cells. Nat Biotechnol. 2014; 32(12): 1223–1230. doi: 10.1038/nbt.3082.Li W, Cavelti-Weder C, Zhang Y, Clement K, Donovan S, Gonzalez G et al. Long-term persistence and development of induced pancreatic β cells generated by lineage conversion of acinar cells. Nat Biotechnol. 2014; 32(12): 1223–1230. doi: 10.1038/nbt.3082.Ariyachet C, Tovaglieri A, Xiang G, Lu J, Shah MS, Richmond CA et al. Reprogrammed stomach tissue as a renewable source of functional β cells for blood glucose regulation. Cell Stem Cell. 2016; 18 (3): 410–421. doi: 10.1016/j.stem.2016.01.003.Ariyachet C, Tovaglieri A, Xiang G, Lu J, Shah MS, Richmond CA et al. Reprogrammed stomach tissue as a renewable source of functional β cells for blood glucose regulation. Cell Stem Cell. 2016; 18 (3): 410–421. doi: 10.1016/j.stem.2016.01.003.Cerda-Esteban N, Naumann H, Ruzittu S, Mah N, Pongrac IM, Cozzitorto C et al. Stepwise reprogramming of liver cells to a pancreas progenitor state by the transcriptional regulator Tgif2. Nature Communications. 2017; 8: 14127. doi: 10.1038/ncomms14127.Cerda-Esteban N, Naumann H, Ruzittu S, Mah N, Pongrac IM, Cozzitorto C et al. Stepwise reprogramming of liver cells to a pancreas progenitor state by the transcriptional regulator Tgif2. Nature Communications. 2017; 8: 14127. doi: 10.1038/ncomms14127.Chera S, Baronnier D, Ghila L, Cigliola V, Jensen JN, Gu G et al. Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producer. Nature. 2014; 514 (7523): 503–507. doi: 10.1038/nature13633.Chera S, Baronnier D, Ghila L, Cigliola V, Jensen JN, Gu G et al. Diabetes recovery by age-dependent conversion of pancreatic δ-cells into insulin producer. Nature. 2014; 514 (7523): 503–507. doi: 10.1038/nature13633.Pileggi A, Molano RD, Ricordi C, Zahr E, Collins J, Valdes R et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006; 81 (9): 1318–1324. doi: 10.1038/nature13633.Pileggi A, Molano RD, Ricordi C, Zahr E, Collins J, Valdes R et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006; 81 (9): 1318–1324. doi: 10.1038/nature13633.Pepper AR. Gala-Lopez B, Pawlick R, Merani S, Kin T, Shapiro AMJ. A prevascularized subcutaneous deviceless site for islet and cellular transplantation. Nat Biotechnol. 2015; 33 (5): 518–523. doi: 10.1038/nbt.3211.Pepper AR. Gala-Lopez B, Pawlick R, Merani S, Kin T, Shapiro AMJ. A prevascularized subcutaneous deviceless site for islet and cellular transplantation. Nat Biotechnol. 2015; 33 (5): 518–523. doi: 10.1038/nbt.3211.Phelps EA, Templeman KL, Thule PM, García AJ. Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization. Drug Deliv Transl Res. 2015; 5 (2): 125–136. doi: 10.1007/s13346-013-0142-2.Phelps EA, Templeman KL, Thule PM, García AJ. Engineered VEGF-releasing PEG-MAL hydrogel for pancreatic islet vascularization. Drug Deliv Transl Res. 2015; 5 (2): 125–136. doi: 10.1007/s13346-013-0142-2.Marchioli G, Luca AD, Koning E. Hybrid polycaprolactone/ alginate scaffolds functionalized with VEGF to promote de novo vessel formation for the transplantation of islets of Langerhans. Adv Healthc Mater. 2016; 5(13): 1606–1616. doi: 10.1002/adhm.201600058.Marchioli G, Luca AD, Koning E. Hybrid polycaprolactone/ alginate scaffolds functionalized with VEGF to promote de novo vessel formation for the transplantation of islets of Langerhans. Adv Healthc Mater. 2016; 5(13): 1606–1616. doi: 10.1002/adhm.201600058.Phelps EA, Headen DM, Taylor WR. Vasculogenic biosynthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes. Biomaterials. 2013; 34 (19): 4602–4611. doi: 10.1016/j.biomaterials.2013.03.012.Phelps EA, Headen DM, Taylor WR. Vasculogenic biosynthetic hydrogel for enhancement of pancreatic islet engraftment and function in type 1 diabetes. Biomaterials. 2013; 34 (19): 4602–4611. doi: 10.1016/j.biomaterials.2013.03.012.Veriter, S. Gianello P, Igarashi Y, Beaurin G, Ghyselinck A, Aouassar N et al. Improvement of subcutaneous bioartificial pancreas vascularization and function by coencapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant. 2014; 23 (11): 1349–1364. doi: 10.3727/096368913X663550.Veriter, S. Gianello P, Igarashi Y, Beaurin G, Ghyselinck A, Aouassar N et al. Improvement of subcutaneous bioartificial pancreas vascularization and function by coencapsulation of pig islets and mesenchymal stem cells in primates. Cell Transplant. 2014; 23 (11): 1349–1364. doi: 10.3727/096368913X663550.Bloch K, Papismedov E, Yavriyants K. Vorobeychik M, Beer S, Vardi P. Photosynthetic oxygen generator for bioartificial pancreas. Tissue Eng. 2006; 12 (2): 337–344. doi: 10.1089/ten.2006.12.337.Bloch K, Papismedov E, Yavriyants K. Vorobeychik M, Beer S, Vardi P. Photosynthetic oxygen generator for bioartificial pancreas. Tissue Eng. 2006; 12 (2): 337–344. doi: 10.1089/ten.2006.12.337.Barkai U, Weir GC, Colton CK, Ludwig B, Bornstein SR, Brendel MD et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant. 2013; 22 (8): 1463–1476. doi: 10.3727/096368912X657341.Barkai U, Weir GC, Colton CK, Ludwig B, Bornstein SR, Brendel MD et al. Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant. 2013; 22 (8): 1463–1476. doi: 10.3727/096368912X657341.Thevenot P, Hu W, Tang L. Surface chemistry influences implant biocompatibility. Curr Top Med Chem. 2008; 8(4): 270–280. doi: 10.2174/156802608783790901.Thevenot P, Hu W, Tang L. Surface chemistry influences implant biocompatibility. Curr Top Med Chem. 2008; 8(4): 270–280. doi: 10.2174/156802608783790901.Zhu H, Li W, Liu Z, Li W, Chen N, Lu L et al. Selection of Implantation Sites for Transplantation of Encapsulated Pancreatic Islets. Tissue Eng Part B Rev. 2018; 24 (3):191–214. doi: 10.1089/ten.TEB.2017.0311.Zhu H, Li W, Liu Z, Li W, Chen N, Lu L et al. Selection of Implantation Sites for Transplantation of Encapsulated Pancreatic Islets. Tissue Eng Part B Rev. 2018; 24 (3):191–214. doi: 10.1089/ten.TEB.2017.0311.Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov. 2017; 16 (5): 338–350. doi: 10.1038/nrd.2016.232.Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov. 2017; 16 (5): 338–350. doi: 10.1038/nrd.2016.232.Muthyala S, Safley S, Gordan K, Barber G, Weber C, Sambanis A. The effect of hypoxia on free and encapsulated adult porcine islets-an in vitro study. Xenotransplantation. 2017; 24 (1). doi: 10.1111/xen.12275.Muthyala S, Safley S, Gordan K, Barber G, Weber C, Sambanis A. The effect of hypoxia on free and encapsulated adult porcine islets-an in vitro study. Xenotransplantation. 2017; 24 (1). doi: 10.1111/xen.12275.Dufrane D, Goebbels RM., Saliez A, Guiot Y, Gianello P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation. 2006; 81 (9): 1345–1353. doi: 10.1097/01.tp.0000208610.75997.20.Dufrane D, Goebbels RM., Saliez A, Guiot Y, Gianello P. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation. 2006; 81 (9): 1345–1353. doi: 10.1097/01.tp.0000208610.75997.20.Vaithilingam V, Evans MD, Rowe A, Bean PA, Tuch BE. Co-encapsulation of Target Effector Cells With Mesenchymal Stem Cells Reduces Pericapsular Fibrosis and Improves Graft Survival in a Xenotransplanted Animal Model. Cell Transplant. 2016; 25 (7): 1299–1317. doi: 10.3727/096368915X688975.Vaithilingam V, Evans MD, Rowe A, Bean PA, Tuch BE. Co-encapsulation of Target Effector Cells With Mesenchymal Stem Cells Reduces Pericapsular Fibrosis and Improves Graft Survival in a Xenotransplanted Animal Model. Cell Transplant. 2016; 25 (7): 1299–1317. doi: 10.3727/096368915X688975.Yang HK, Yoon KH. Current status of encapsulated islet transplantation. J Diabetes Complications. 2015; 29 (5):737–743. doi: 10.1016/j.jdiacomp.2015.03.017.Yang HK, Yoon KH. Current status of encapsulated islet transplantation. J Diabetes Complications. 2015; 29 (5):737–743. doi: 10.1016/j.jdiacomp.2015.03.017.US National Library of Medicine. ClinicalTrials.gov. [Internet] A Phase I/II Study of the Safety and Efficacy of Sernova’s Cell PouchTM for Therapeutic Islet Transplantation. Available from: https://clinicaltrials.gov/ct2/show/NCT01652911.US National Library of Medicine. ClinicalTrials.gov. [Internet] A Phase I/II Study of the Safety and Efficacy of Sernova’s Cell PouchTM for Therapeutic Islet Transplantation. Available from: https://clinicaltrials.gov/ct2/show/NCT01652911.US National Library of Medicine. ClinicalTrials.gov [Internet]. Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT01739829.US National Library of Medicine. ClinicalTrials.gov [Internet]. Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT01739829.US National Library of Medicine. ClinicalTrials.gov [Internet] Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00790257.US National Library of Medicine. ClinicalTrials.gov [Internet] Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00790257.US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01379729(2013).US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01379729(2013).US National Library of Medicine. ClinicalTrials.gov [Internet] A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT02239354.US National Library of Medicine. ClinicalTrials.gov [Internet] A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT02239354.US National Library of Medicine. ClinicalTrials.gov [Internet] An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macroencapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT02064309.US National Library of Medicine. ClinicalTrials.gov [Internet] An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macroencapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus. Available from: https://clinicaltrials.gov/ct2/show/NCT02064309.US National Library of Medicine. ClinicalTrials.gov [Internet] Allogeneic Islet Cells Transplanted Onto the Omentum. Available from: https://clinicaltrials.gov/ct2/show/NCT02213003.US National Library of Medicine. ClinicalTrials.gov [Internet] Allogeneic Islet Cells Transplanted Onto the Omentum. Available from: https://clinicaltrials.gov/ct2/show/NCT02213003.Tan PL. Company profile: Tissue regeneration for diabetes and neurological diseases at living cell technologies. Regen Med. 2010; 5 (2): 181–187. doi: 10.2217/rme.10.4.Tan PL. Company profile: Tissue regeneration for diabetes and neurological diseases at living cell technologies. Regen Med. 2010; 5 (2): 181–187. doi: 10.2217/rme.10.4.Carlsson P-O, Espes D, Sedigh A. Transplantation of macroencapsulated human islets within the bioartificial pancreas βAir to patients with type 1 diabetes mellitus. Am J Transplant. 2018; 18 (7): 1735–1744. doi: 10.1111/ajt.14642.Carlsson P-O, Espes D, Sedigh A. Transplantation of macroencapsulated human islets within the bioartificial pancreas βAir to patients with type 1 diabetes mellitus. Am J Transplant. 2018; 18 (7): 1735–1744. doi: 10.1111/ajt.14642.Baidal DA, Ricordi C, Berman DM, Alvarez A, Padilla N, Ciancio et al. Bioengineering of an intraabdominal endocrine pancreas. N Engl J Med. 2017; 376 (19):1887–1889. doi: 10.1056/NEJMc1613959.Baidal DA, Ricordi C, Berman DM, Alvarez A, Padilla N, Ciancio et al. Bioengineering of an intraabdominal endocrine pancreas. N Engl J Med. 2017; 376 (19):1887–1889. doi: 10.1056/NEJMc1613959.Niu D, Wei HJ, Lin L, George H, Wang T, Lee I-H. Inactivation of porcine endogenous retrovirus in pigs using CRISPR–Cas9. Science. 2017; 357 (6357): 1303–1307. doi: 10.1126/science.aan4187.Niu D, Wei HJ, Lin L, George H, Wang T, Lee I-H. Inactivation of porcine endogenous retrovirus in pigs using CRISPR–Cas9. Science. 2017; 357 (6357): 1303–1307. doi: 10.1126/science.aan4187.Yang L, Güell M, Niu D, George H, Lesha E, Grishin D et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science. 2015; 350 (6264): 1101–1004. doi: 10.1126/science.aad1191.Yang L, Güell M, Niu D, George H, Lesha E, Grishin D et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). Science. 2015; 350 (6264): 1101–1004. doi: 10.1126/science.aad1191.

The authors declare that there are no conflicts of interest present.